Metabolic drug development: pipeline, trials and approval odds
Obesity, type 2 diabetes, and metabolic liver disease drug development: active industry trials, historical approval odds, and the incretin and amylin drugs reshaping the field.
Key points
- Obesity has become one of the most active areas of drug development. On ClinicalTrials.gov, Eli Lilly and Novo Nordisk are by far the most active industry sponsors of Phase 3 trials in the area.
- Historically, the BIO analysis's Metabolic category had one of the best likelihoods of approval: 15.5% from Phase 1, second only to hematology, roughly double the all-disease average of 7.9%.
- The field has moved from single-hormone drugs (GLP-1 agonists such as semaglutide) to combinations: GIP plus GLP-1 (tirzepatide), triple agonists (retatrutide), and amylin combinations (CagriSema).
- The FDA approved the first oral small-molecule GLP-1 drug for weight management, orforglipron (Foundayo), on April 1, 2026.
- Competition is increasingly decided head to head: CagriSema did not show non-inferiority to tirzepatide in REDEFINE 4.
Active industry trials
About 657 industry-sponsored Phase 1–3 trials in this area are active on ClinicalTrials.gov (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts come from condition searches; a trial listing several conditions can appear in more than one row.
| Condition | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
| Obesity and overweight | 176 | 92 | 155 |
| Type 2 diabetes | 72 | 70 | 112 |
| Fatty liver disease (MASH/NASH) | 27 | 33 | 24 |
| Whole area | 240 | 173 | 244 |
Most active Phase 3 sponsors
- Eli Lilly and Company (41 active Phase 3 trials)
- Novo Nordisk A/S (35 active Phase 3 trials)
- Pfizer (13 active Phase 3 trials)
- Amgen (12 active Phase 3 trials)
- AstraZeneca (11 active Phase 3 trials)
- Hoffmann-La Roche (10 active Phase 3 trials)
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (9 active Phase 3 trials)
- Gan & Lee Pharmaceuticals. (8 active Phase 3 trials)
Historical approval odds
Share of programs at each stage that went on to FDA approval, 2011–2020.
| Disease area (as defined by the source) | From Phase 1 | From Phase 2 | From Phase 3 | From submission |
|---|---|---|---|---|
| Metabolic (n = 399) | 15.5% | 25% | 55.7% | 87.5% |
| Endocrine (n = 887) | 6.6% | 15.2% | 57.1% | 86.3% |
| All indications (n = 12,728) | 7.9% | 15.1% | 52.4% | 90.6% |
Source: BIO, Informa Pharma Intelligence, QLS Advisors (2021), likelihood-of-approval table (Figure 5b). The report does not publish which conditions it assigns to each disease area, so obesity and diabetes programs could fall under its Metabolic or Endocrine category. Both rows are shown. These are averages for groups of programs, not predictions for any drug. See our methodology.
Tracked drugs in this area
Orforglipron (Foundayo)
Eli Lilly and Company · Small molecule (oral, once daily)
FDA-approved for chronic weight management (April 2026); type 2 diabetes submitted in the U.S.
Not yet approvedRetatrutide
Eli Lilly and Company · Peptide (once-weekly injection)
Phase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027
Not yet approvedCagriSema
Novo Nordisk · Peptide combination (once-weekly injection)
Submitted to the FDA in December 2025 for weight management; decision expected in late 2026 (company-reported)
The incretin era
Incretins are gut hormones released after eating that reduce appetite and help control blood sugar. Drugs that mimic them, starting with GLP-1 receptor agonists, turned obesity from an area with few effective medicines into one of the most crowded fields in drug development.
| Approach | Example | How it differs | Status |
|---|---|---|---|
| GLP-1 receptor agonist (injection) | Semaglutide | One hormone pathway | Approved (Wegovy, Ozempic) |
| GIP + GLP-1 agonist | Tirzepatide | Two pathways in one molecule | Approved (Zepbound, Mounjaro) |
| Oral small-molecule GLP-1 agonist | Orforglipron | A pill, without food or water restrictions (company-reported) | FDA-approved April 2026 (Foundayo) |
| Amylin + GLP-1 combination | CagriSema | Adds the amylin pathway | Submitted to the FDA (company-reported) |
| GIP + GLP-1 + glucagon agonist | Retatrutide | Three pathways; largest reported weight loss | Phase 3 complete; FDA filing planned Q1 2027 (company-reported) |
How the competition is being decided
With several effective drugs approved, new entrants increasingly have to beat, or at least match, existing ones:
- Magnitude. Retatrutide's Phase 2 trial produced 24.2% weight loss at 48 weeks on its highest dose, and Lilly reported 28.3% at 80 weeks in Phase 3 (company-reported).
- Head-to-head trials. CagriSema produced 20.4% weight loss against placebo in REDEFINE 1, but did not show non-inferiority to tirzepatide in REDEFINE 4.
- Convenience. Orforglipron produces more modest weight loss (11.2% at 72 weeks on its highest dose in ATTAIN-1) but is a daily pill rather than an injection.
- Outcomes beyond weight. Companies are running cardiovascular, kidney, sleep apnea, and osteoarthritis trials to show health benefits beyond weight loss.
What the approval odds mean here
Metabolic programs have historically been more likely than average to reach approval, partly because weight and blood sugar respond quickly and are measured objectively, so trials are shorter and clearer than in many areas. Even so, the historical rates describe groups of programs. For any individual drug, tolerability, especially gastrointestinal side effects, and differentiation from approved competitors are now central risks.
Metabolic liver disease
The registry table includes industry trials in fatty liver disease (MASH/NASH), an area where several incretin drugs are also being tested. Spectral Genomics does not yet profile drugs specifically developed for it.
Company pipelines
- Eli Lilly and Company · NYSE: LLY
- Novo Nordisk · NYSE: NVO
- Amgen · Nasdaq: AMGN
Sources
- U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher program (April 1, 2026).Regulator
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526.Peer-reviewed
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025;393(7):635–647.Peer-reviewed
- Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine. 2025;393(18):1796–1806.Peer-reviewed
- Novo Nordisk A/S. Form 6-K (February 23, 2026): REDEFINE 4 results.Company-reported
- BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
- ClinicalTrials.gov: active industry trials in this areaRegistry
For education and research only. Not medical advice and not investment advice. See our disclaimer.